Allakos Inc 2025年季度报告

For the quarterly period endedMarch 31,2025 Allakos Inc. Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of theSecurities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ ALLAKOS INC.Table of Contents PART I.FINANCIAL INFORMATIONItem 1.Financial Statements (Unaudited)Balance SheetsStatements of Operations and Comprehensive LossStatements of Stockholders’ EquityStatements of Cash FlowsNotes to Unaudited Interim Financial StatementsItem 2.Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3.Quantitative and Qualitative Disclosures About Market RiskItem 4.Controls and ProceduresPART II.OTHER INFORMATIONItem 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.ExhibitsSignatures PART I—FINANCIAL INFORMATION ALLAKOS INC.BALANCESHEETS(in thousands, except per share data) ALLAKOS INC.STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS ALLAKOS INC.NOTES TO UNAUDITED INTERIM FINANCIAL STATEMENTS 1. Organization and Business Allakos Inc. (“Allakos” or the “Company”) was incorporated in the State of Delaware in March 2012. Allakos is a clinicalstage biopharmaceutical company with intellectual property regarding therapeutics that target immunomodulatory receptors presenton immune effector cells involved in allergic, inflammatory and proliferative diseases. The Company’s primary activities to datehave included establishing its facilities, recruiting personnel, conducting research and development of its product candidates and On April 1, 2025, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with ConcentraBiosciences, LLC, a Delaware limited liability company (“Concentra”), and Concentra Merger Sub III, Inc., a Delawarecorporation and a wholly owned subsidiary of Concentra (“Merger Sub”). The Merger Agreement provides for, among otherthings: (i) the acquisition of all of the Company’s outstanding shares of common stock, par value $0.001per share (the “CommonStock”) by Concentra through a cash tender offer (the “Offer”) by Merger Sub, for a price per share of the Common Stock of $0.33 The Company’s operations are located in Menlo Park, California. The Company operates inonereportable segment. Liquidity Matters Since inception, the Company has incurred net losses and negative cash flows from operations. During the three monthsended March 31, 2025, the Company incurred a net loss of$26.2million. At March 31, 2025, the Company had an accumulateddeficit of$1,260.5millionand does not expect to experience positive cash flows from operating activities in the foreseeable future. In January 2025, we announced that our product candidate, AK006, did not demonstrate therapeutic activity in patients withChronic Spontaneous Urticaria (CSU) in our Phase 1 multicenter, randomized, double-blind, placebo-controlled clinical trial. Wefurther announced our intention to discontinue further development of AK006 and we launched a comprehensive review of In order to maximize capital preservation, the Company’s Board of Directors (the “Board”) approved a reorganization plan inJanuary 2025 (the “2025 Reorganization Plan”) to reduce the Company’s workforce by approximately75%, with remainingemployees retained to explore strategic alternatives, maintain compliance with regulatory and financial reporting requirements, and If the Merger is effected, the Common Stock will be delisted from The Nasdaq Stock Market LLC and the Company’sobligation to file periodic reports under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) will terminate, andthe Company will be privately held. If the Merger is not completed and another strategic alternative is not identified, the Board may The Company had$55.2millionof cash, cash equivalents and investments at March 31, 2025. Management believes that thisamount is sufficient to fund the Company’s operations for at least the next 12 months from the issuance date of these financial 2. S